Related Experiment Videos
A phase II trial of fludarabine in patients with previously treated chronic lymphocytic leukaemia
A M Hocepied1, C I Falkson, G Falkson
1Department of Medical Oncology, University of Pretoria.
Abstract
Objectives:
To evaluate fludarabine in patients with chronic lymphocytic leukaemia (CLL) not responding to standard treatment.
Design Setting:
Fludarabine was administered for 5 consecutive days and repeated 4-weekly.
Subjects:
Seventeen patients at a single institution were treated.
Outcome Measures:
Objective remission was seen in 11 patients. The median survival time was 356 days.
Results And Conclusions:
Fludarabine is an effective treatment for patients with advanced CLL.